Introduction
chronic myeloid leukemia, TFR
CHRONIC MYELOID LEUKEMIA, REMISSION
Edited by: Cinzia Fionda, Sapienza University of Rome, ItalyReviewed by: Gerard Bos, Maastricht University Medical Centre, Netherlands; Juan Bautista De Sanctis, Palacký University Olomouc, CzechiaTreatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic phase is considered a safe option if suitable molecular monitoring is available. However, the question arises as to which factors can contribute to the maintenance of TFR, and immunologic surveillance of the remaining leukemic cells is believed to be one of them. Argentina Stop Trial is an open-label, single-arm, multicenter trial assessing TFR after tyrosine kinase inhibitors interruption, that after more than 4 years showed a successful TFR rate of 63%.